# US 2025/0347701 A1 · Methods for monitoring molecular biomarkers for aging and disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0347701 A1
- Document ID: US20250347701A1
- Status: Published application
- Kind: A1
- Application number: 18/997,478
- Filed: 2023-09-25
- Published: 2025-11-13
- Earliest claimed: 2022-08-01
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Vinit MAHAJAN; Julian WOLF
- Web page: https://patentgrep.com/patent/US20250347701A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/5751: of the skin, e.g. melanoma
- C07K 2318/00: Antibody mimetics or scaffolds
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- G01N 2333/4753: Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
- G01N 2333/49: Platelet-derived growth factor [PDGF]
- G01N 2800/16: Ophthalmology
- G01N 2800/164: Retinal disorders, e.g. retinopathy
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Compositions, methods, and kits are provided for diagnosing vitreoretinal diseases and age-related pathologies. In particular, aqueous humor biomarkers have been identified that correlate with biological aging and age-related pathologies and morbidity. The use of such biomarkers may allow earlier intervention in treatment of aging-related diseases. In addition, methods of using aqueous humor biomarkers for prognosis, diagnosis, and monitoring treatment of vitreoretinal diseases are also provided.

## Claims

### Claim 1

A method of diagnosing and treating age-related macular degeneration (AMD) in a patient, the method comprising:
obtaining an aqueous humor sample from an eye of the patient;
measuring levels of one or more biomarkers selected from serpin family F member 1 (SERPINF1), vascular endothelial growth factor A (VEGFA), fins related receptor tyrosine kinase 1 (FLT1), vascular endothelial growth factor B (VEGFB), and vascular endothelial growth factor D (VEGFD) in the aqueous humor sample, wherein increased levels of the one or more biomarkers selected from SERPINF1, VEGFA, FLT1, VEGFB, and VEGFD compared to reference value ranges for the levels of the one or more biomarkers in a control aqueous humor sample indicate that the patient has AMD; and
treating the patient for the AMD if the patient has a positive diagnosis for AMD.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, wherein the levels of SERPINF1, VEGFA, FLT1, VEGFB, and VEGFD are measured in the aqueous humor sample.

### Claim 4 (depends on 1)

The method of claim 1, wherein said treating the patient for the AMD comprises administering vitamin C, zinc, vitamin E, copper, beta-carotene, lutein, zeaxanthin, ranibizumab, aflibercept, brolucizumab, or faricimab, or a combination thereof to the patient.

### Claim at position 5

5-18. (canceled)

### Claim 19

A method of diagnosing and treating diabetic retinopathy in a patient, the method comprising:
obtaining an aqueous humor sample from an eye of the patient;
measuring levels of one or more biomarkers selected from serpin family F member 1 (SERPINF1), retinoic acid receptor responder 2 (RARRES2), complement factor I (CFI), amyloid beta precursor protein (APP), complement C4A (C4A), and complement C4B (C4B) in the aqueous humor sample, wherein increased levels of the one or more biomarkers selected from SERPINF1, RARRES2, CFI, APP, C4A, and C4B compared to reference value ranges for the levels of the one or more biomarkers in a control aqueous humor sample indicate that the patient has diabetic retinopathy; and
treating the patient for the diabetic retinopathy if the patient has a positive diagnosis for diabetic retinopathy.

### Claim 20

(canceled)

### Claim 21 (depends on 19)

The method of claim 19, wherein the levels of SERPINF1, RARRES2, CFI, APP, C4A, and C4B are measured in the aqueous humor sample.

### Claim 22 (depends on 19)

The method of claim 19, wherein said treating the patient for the diabetic retinopathy comprises administering an anti-vascular endothelial growth factor (VEGF) agent or a steroid, or performing panretinal laser photocoagulation or a vitrectomy, or a combination thereof.

### Claim at position 10

23-38. (canceled)

### Claim 39

A method of diagnosing and treating proliferative vitreoretinopathy (PVR) in a patient, the method comprising:
obtaining an aqueous humor sample from an eye of the patient;
measuring levels of one or more biomarkers selected from insulin like growth factor binding protein 6 (IGFBP6), C-C motif chemokine ligand 15 (CCL15), C-X-C motif chemokine ligand 12 (CXCL12), vascular endothelial growth factor A (VEGFA), and C-C motif chemokine ligand 23 (CCL23) in the aqueous humor sample, wherein increased levels of the one or more biomarkers selected from IGFBP6, CCL15, CXCL12, VEGFA, and CCL23 compared to reference value ranges for the levels of the one or more biomarkers in a control aqueous humor sample indicate that the patient has PVR; and
treating the patient for the PVR if the patient has a positive diagnosis for PVR.

### Claim 40

(canceled)

### Claim 41 (depends on 39)

The method of claim 39, wherein the levels of IGFBP6, CCL15, CXCL12, VEGFA, and CCL23 are measured in the aqueous humor sample.

### Claim 42 (depends on 39)

The method of claim 39, wherein said treating the patient for the PVR comprises performing vitreous surgery, vitrectomy, membrane peeling, or retinotomy.

### Claim at position 15

43-56. (canceled)

### Claim 57

A method of diagnosing and treating melanoma in a patient, the method comprising:
obtaining an aqueous humor sample from an eye of the patient;
measuring levels of one or more biomarkers selected from follistatin like 1 (FSTL1), ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2), angiogenin (ANG), MET proto-oncogene, receptor tyrosine kinase (MET), and hepatocyte growth factor (HGF) in the aqueous humor sample, wherein increased levels of the one or more biomarkers selected from FSTL1, ENPP2, ANG, MET, and HGF compared to reference value ranges for the levels of the one or more biomarkers in a control aqueous humor sample indicate that the patient has melanoma; and
treating the patient for the melanoma if the patient has a positive diagnosis for melanoma.

### Claim 58

(canceled)

### Claim 59 (depends on 57)

The method of claim 57, wherein the levels of FSTL1, ENPP2, ANG, MET, and HGF are measured in the aqueous humor sample.

### Claim 60 (depends on 57)

The method of claim 57, wherein said treating the patient for the melanoma comprises performing surgery to excise the melanoma.

### Claim 61 (depends on 60)

The method of claim 60, wherein said treating further comprises performing radiation therapy or administering interferon, interleukin-2 (IL-2), dacarbazine, vemurafenib, dabrafenib, trametinib, pembrolizumab, ipilimumab, tremelimumab, nivolumab/relatlimab, or imiquimod, or a combination thereof.

### Claim at position 21

62-77. (canceled)

### Claim 78

A method of diagnosing and treating uveitis in a patient, the method comprising:
obtaining an aqueous humor sample from an eye of the patient;
measuring levels of one or more biomarkers selected from retinoic acid receptor responder 2 (RARRES2), biotinidase (BTD), cystatin C (CST3), TIMP metallopeptidase inhibitor 2 (TIMP2), and prostaglandin D2 synthase (PTGDS) in the aqueous humor sample, wherein increased levels of the one or more biomarkers selected from RARRES2, BTD, CST3, TIMP2, and PTGDS compared to reference value ranges for the levels of the one or more biomarkers in a control aqueous humor sample indicate that the patient has uveitis; and
treating the patient for the uveitis if the patient has a positive diagnosis for uveitis.

### Claim 79

(canceled)

### Claim 80 (depends on 78)

The method of claim 78, wherein the levels of RARRES2, BTD, CST3, TIMP2, and PTGDS are measured in the aqueous humor sample.

### Claim 81 (depends on 78)

The method of claim 78, wherein said treating the patient for the uveitis comprises administering a glucocorticoid steroid, a cycloplegic agent, an antimetabolite, a T-cell inhibitor, an anti-tumor necrosis factor (TNF) agent, a biologic agent, an alkylating agent, an antibiotic for bacterial uveitis, an antiviral agent for viral uveitis, or an antifungal agent for fungal uveitis, or performing a vitrectomy, or a combination thereof.

### Claim at position 26

82-95. (canceled)

### Claim 96

A method of diagnosing and treating neovascular inflammatory vitreoretinopathy (NIV) in a patient, the method comprising:
obtaining an aqueous humor sample from an eye of the patient;
measuring levels of one or more biomarkers selected from serpin family C member 1 (SERPINC1), hemopexin (HPX), coagulation factor II (F2), complement C9 (C9), and complement C6 (C6) in the aqueous humor sample, wherein increased levels of the one or more biomarkers selected from SERPINC1, HPX, F2, C9, and C6 compared to reference value ranges for the levels of the one or more biomarkers in a control aqueous humor sample indicate that the patient has neovascular inflammatory vitreoretinopathy (NIV); and
treating the patient for the neovascular inflammatory vitreoretinopathy (NIV) if the patient has a positive diagnosis for neovascular inflammatory vitreoretinopathy (NIV).

### Claim 97

(canceled)

### Claim 98 (depends on 96)

The method of claim 96, wherein the levels of SERPINC1, HPX, F2, C9, and C6 are measured in the aqueous humor sample.

### Claim 99 (depends on 96)

The method of claim 96, wherein said treating the patient for the neovascular inflammatory vitreoretinopathy comprises administering fluocinolone acetonide, dexamethasone, or bevacizumab, or performing panretinal scatter photocoagulation (PRP), vitrectomy, trabeculectomy, or a combination thereof.

### Claim at position 31

100-113. (canceled)

### Claim 114

A method of predicting biological age and determining risk of age-related pathology and morbidity in a patient, the method comprising:
obtaining an aqueous humor sample from an eye of the patient;
measuring levels of one or more biomarkers selected from stromelysin-2 (MMP10), neuropilin-1 (NRP1), semaphorin 3C (SEMA3C), hes family bHLH transcription factor 5 (HES5), and fibroblast growth factor receptor like 1 (FGFRL1) in the aqueous humor sample, wherein decreased levels of the one or more biomarkers selected from MMP10, NRP1, SEMA3C, HES5, and FGFRL1 compared to reference value ranges for the levels of the one or more biomarkers in a control aqueous humor sample indicate that the patient has a risk of age-related pathology and morbidity; and
increasing screening of the patient for an aging-related disease if the patient is identified as having the risk age-related pathology and morbidity.

### Claim 115 (depends on 114)

The method of claim 114, further comprising administering a treatment for the aging-related disease to the patient if the patient is identified as having the aging-related disease.

### Claim 116

A method of monitoring biological aging of an eye in a patient, the method comprising:
obtaining an aqueous humor sample from an eye of the patient; and
measuring levels of one or more biomarkers selected from stromelysin-2 (MMP10), neuropilin-1 (NRP1), semaphorin 3C (SEMA3C), hes family bHLH transcription factor 5 (HES5), and fibroblast growth factor receptor like 1 (FGFRL1) in the aqueous humor sample, wherein levels of the one or more biomarkers selected from MMP10, NRP1, SEMA3C, HES5, and FGFRL1 are correlated with biological age of the eye.

### Claim 117

(canceled)

### Claim 118 (depends on 117)

The method of claim 117, wherein the levels of MMP10, NRP1, SEMA3C, HES5, and FGFRL1 are measured in the aqueous humor sample.

### Claim at position 37

119-128. (canceled)
